Skip to content

Treatment of advanced oral and maxillofacial - head and neck malignant tumor by ultrasonic tumor hyperthermia

Clinical Trial of Ultrasound Tumor Hyperthermia in the Treatment of Advanced Oral and Maxillofacial - Head and Neck Malignant Tumors

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800014391
Enrollment
Unknown
Registered
2018-01-10
Start date
2014-12-09
Completion date
Unknown
Last updated
2018-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Squamous cell carcinoma of oral cavity

Interventions

Group:Chemotherapy combined with ultrasonic heating
Control group:Chemotherapy

Sponsors

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Age over 18 years old (including 18 years old), under 75 years old (including 75 years old), male and female; (2) diagnosis of oral squamous cell carcinoma by histopathology; (3) ECOG score 0 to 2 points, is expected to live longer than 6 months; (4) clinical staging in line with local advanced (III ~ IV, refer to the seventh edition UICC / AJCC staging system [22]), including unresectable tumors; (5) before the trial signed informed consent, voluntarily participate in the test; (6) good compliance; (7) blood, blood sugar and liver, kidney, lung function and other normal; (8) female pregnancy test subjects pregnancy test negative, must agree to use effective contraceptive measures to ensure that during the trial and stop treatment within 3 months after pregnancy is not pregnant.

Exclusion criteria

Exclusion criteria: (1) failure to obtain signed informed consent; (2) pregnant, lactating women; (3) vital organs dysfunction, the existence of life-threatening; (4) patients who have received radiotherapy locally; (5) local skin ulceration, open wound; (6) clear distant metastases or other malignancies; (7) known to have allergic reactions to chemotherapy drugs; (8) suffering from mental illness, can not cooperate with the treatment; (9) have febrile disease, can not control the symptoms; (10) abnormal coagulation, bleeding tendency; (11) had participated in other clinical trials in the past 30 days; (12) other investigators believe that inappropriate treatment of the situation.

Design outcomes

Primary

MeasureTime frame
Target lesion diameter;

Countries

China

Contacts

Public ContactGuo Wei

Shanghai Jiaotong University School of Medicine Affiliated Ninth People's Hospital

18662599288@163.com+86 13901685814

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026